EP0447476A1 - Nouveaux peptides derives du facteur de necrose de tumeurs (tnf) - Google Patents

Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)

Info

Publication number
EP0447476A1
EP0447476A1 EP90900861A EP90900861A EP0447476A1 EP 0447476 A1 EP0447476 A1 EP 0447476A1 EP 90900861 A EP90900861 A EP 90900861A EP 90900861 A EP90900861 A EP 90900861A EP 0447476 A1 EP0447476 A1 EP 0447476A1
Authority
EP
European Patent Office
Prior art keywords
pro
group
glu
gly
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP90900861A
Other languages
German (de)
English (en)
Inventor
Hans-Joachim Boehm
Lothar Daum
Andreas Haupt
Bernhard Schmied
Nigel Walker
Johann-Christian Zechel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of EP0447476A1 publication Critical patent/EP0447476A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • New TNF peptides Description The invention relates to new peptides derived from tumor necrosis factor (TNF), their production and their use as medicaments.
  • TNF tumor necrosis factor
  • TNF is one of the main participants in inflammatory reactions (Pharmac. Res. 5, 129, 1988). in the Animal models showed the involvement of TNF in septic shock (Science 229, 869, 1985) and graft versus host disease (J. Exp. Med. 166, 1280, 1987). It has now been found that peptides with a significantly lower molecular weight have favorable properties.
  • the invention relates to peptides of the formula I, X-A-Y I,
  • Y for a group -Z, -NH-CHQ-CO-Z, -V-NH-CHQ-CO-Z, -NH-CHQ-CO-U-Z or
  • G represents a hydrogen atom or an amino protecting group
  • Z represents an OH or NH2 group or a carboxyl protecting group
  • M and Q are hydrogen atoms or one of the groups
  • M and Q together form a - (CH 2 ) c -SS- (CH 2 ) d -, - (CH 2 ) e -CO-NH- (CH 2 ) f - or - (CH 2 ) e -NH-CO- (CH 2 ) g -NH-CO- (CH 2 ) f bridge (with c and d meaning a number from 1 to 4, e and f a number from 1 to 6 and g a number from 1 to 12) mean, and their salts with physiologically acceptable acids.
  • the peptides of formula I are made up of L-amino acids, but they can contain 1 to 2 D-amino acids.
  • the side chains of the trifunctional amino acids can carry protective groups or be unprotected.
  • Methanesulfonic acid acetic acid, formic acid, maleic acid, fumaric acid, malic acid, succinic acid, malonic acid, sulfuric acid, L-glutamic acid, L-aspartic acid, pyruvic acid, mucic acid, benzoic acid,
  • Glucuronic acid oxalic acid, ascorbic acid, acetylglycine.
  • the new compounds can be prepared by methods known in peptide chemistry.
  • the fragments in turn being able to be obtained by sequential construction from amino acids or in turn by fragment coupling.
  • the cyclic peptides are obtained by a cyclization reaction carried out in high dilution. Both in the sequential structure and in the fragment coupling, the building blocks must be linked by forming an amide bond. Enzymatic and chemical methods are suitable for this.
  • the coupling reagents can be used alone or in combination with additives such as N, N'-dimethyl-4-aminopyridine (DMAP), N-hydroxybenzotriazole (HOBt), N-hydroxybenzotriazine (HOOBt), N-hydroxysuccinimide (HOSu) or 2-hydroxypyri.din be used.
  • DMAP N, N'-dimethyl-4-aminopyridine
  • HOBt N-hydroxybenzotriazole
  • HOOBt N-hydroxybenzotriazine
  • HSu N-hydroxysuccinimide
  • 2-hydroxypyri.din 2-hydroxypyri.din be used.
  • protective groups can be dispensed with, chemical synthesis requires reversible protection of the reactive functional groups of the two reactants which are not involved in the formation of the amide bond.
  • three protecting group techniques known from the literature are preferred: the benzyloxycarbonyl (Z), the t-butyloxycarbonyl (Boc) and the 9-fluorenylmethyloxycarbonyl (Fmoc) protective group technique.
  • the protective group of the ⁇ -amino function of the chain-extending building block is designated in each case.
  • the side chain protecting groups of the trifunctional amino acids are chosen so that they are not necessarily split off together with the ⁇ -amino protecting group.
  • the peptide is typically built up sequentially on the polymeric support using the Boc or Fmoc protective group technique, the growing peptide chain at the C-terminus being covalently linked to the insoluble resin particles (see Figs. 1 and 2). This procedure allows reagents and by-products to be removed by filtration, which means that the recrystallization of intermediate products becomes superfluous.
  • the protected amino acids can be bound to any suitable polymers which are only insoluble in the solvents used and must have a stable physical form which enables easy filtration.
  • the polymer must contain a functional group to which the first protected amino acid can be bound by a covalent bond.
  • a wide variety of polymers are suitable for this purpose, e.g.
  • All solvents which prove inert under the reaction conditions are suitable for peptide synthesis in solution, in particular water, N, N'-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, dichloromethane (DCM), 1,4-dioxane, Tetrahydrofuran (THF), N-methyl-2-pyrrolidone (NMP) and mixtures of the solvents mentioned.
  • the peptide synthesis on the polymeric support can be carried out in all inert organic solvents in which the amino acid derivatives used are soluble; however, solvents which additionally have resin-swelling properties, such as DMF, DCM, NMP, acetonitrile and DMSO, and mixtures of these solvents are preferred.
  • the new peptides show good cytotoxic properties. Another part of the peptides has a high affinity for the cellular TNF receptor without, however, having any cytotoxic activity. They therefore represent TNF antagonists. In competition with natural TNF, they bind to the cellular TNF receptor and thus suppress the TNF effect.
  • the new peptides prove to be valuable medicinal products that are used for
  • neoplastic diseases and autoimmune diseases Treatment of neoplastic diseases and autoimmune diseases as well as for the control and prophylaxis of infections, inflammation and
  • Rejection reactions can be used in transplants. Simple experiments can be used to determine the mode of action of the individual peptides.
  • Simple experiments can be used to determine the mode of action of the individual peptides.
  • Cytotoxicity of the peptide was determined by incubating the cell line in the presence of the peptide. In a second experiment, you incubate the
  • the agonistic evaluation of the new peptides is based on their cytotoxic effects on TNF-sensitive cells (e.g. L929, MCF-7,
  • the L929 and MCF-7 test was performed as follows: 1. 100 ⁇ l of culture medium with 3 to 5 ⁇ 10 3 freshly trypsinized, exponentially growing L929 cells (mouse) or MCF-7 cells (human) were placed in the wells of a
  • the L929 culture medium contained 500 ml MEM Earle 1 ⁇ (Boehringer, Mannheim), 50 ml heat-inactivated (30 min, 56 ° C.) fetal calf serum (FCS), 50 ml L-glutamine (200 mM), 5 ml 100 ⁇
  • non-essential amino acids 3 ml 1M Hepes buffer pH 7.2 and 50 ml gentamycin (50 mg / ml).
  • the MCF-7 culture medium contained 500 ml of MEM Dulbecco 1x
  • the percentage of surviving cells in the cultures treated with peptide dilution was determined by means of crystal violet staining.
  • the liquids were removed from the wells by knocking off the test plate. 50 ⁇ l of crystal violet solutions were pipetted into each well.
  • the crystal violet solution had the following composition:
  • the antagonistic evaluation of the peptides is based on their
  • TNF-sensitive cells e.g. L929, MCF-7, A204, U937.
  • the L929 culture medium contained 500 ml MEM Earle 1 ⁇ (Boehringer, Mannheim), 50 ml FCS heat-inactivated for 30 min at 56 ° C., 5 ml L-glutamine (200 mM), 5 ml 100 ⁇ non-essential amino acids, 3 ml 1M Hepes Buffer pH 7.2 and 500 ul Ge ⁇ tamycin (50 mg / ml).
  • the MCF-7 culture medium contained 500 ml MEM Dulbecco 1x (Boehringer, Mannheim), 100 ml heat-inactivated (30 min, 56 ° C) FCS, 5 ml L-glutamine (200 mM) and 5 ml 100x nonessential amino acids. 2. The next day 100 ⁇ l of the peptide solution to be tested were added to the cell cultures and titrated twice in series. These cell cultures were then 100 ⁇ l of a rhu-TNF dilution in culture medium, which in the final concentration in the cell culture Has 80-100% cytotoxic effect. In addition, some cell controls (ie, cell cultures not treated with peptide solution and not with rhu-TNF solution) and some
  • the percentage of surviving cells in the solution-treated cultures was determined by crystal violet staining.
  • the liquids were removed from the wells by knocking off the test plate. 50 ⁇ l of crystal violet solutions were pipetted into each well.
  • the crystal violet solution had the one given in II.3
  • the crystal violet solution remained in the wells for 20 min and was then also knocked off.
  • the plates were then washed 5 times each by immersion in water to remove the non-cell-bound dye.
  • cell-bound dye was added by adding 100 ul
  • Reagent solution (50% ethanol, 0.1% glacial acetic acid, 49.9% water) was extracted from the cells into each well. 4. By shaking the plates for 5 min each was obtained
  • rhu-TNF control defined the 50% competition value and the sample concentration, which leads to 50% competition of the rhu-TNF cytotoxicity at the presented rhu-TNF concentration, was determined as the antagonistic activity of the examined sample.
  • Indicator cells (eg U937) compete.
  • the medium contained 500 ml PBS (Boehringer, Mannheim), 10 ml heat-inactivated (30 min, 56 ° C) FCS and 100 mg sodium azide.
  • rhu-TNF lactoperoxidase method according to Bolton
  • NBS nonspecific binding
  • the 125 iodine-labeled rhu-TNF (1 ng 125 J-rhu-TNF in 100 ⁇ l medium) with a 200-fold excess of non-radioactively labeled rhu-TNF (200 ng rhu-TNF mixed in 100 ul medium).
  • 100 ⁇ l of medium with 2 ⁇ 10 6 u937 cells (human) were pipetted into the reaction vessels and mixed.
  • the reaction vessels (test volume 300 ⁇ l) were incubated at 0 ° C. for 90 min. After 45 minutes, the reaction batches were mixed again.
  • proteogenic amino acids are in the examples with the known proteogenic amino acids
  • the peptide resin obtained according to la was dried in a vacuum and transferred into a reaction vessel of a Teflon HF apparatus (from PENINSULA). After adding a scavenger, preferably anisole (1 ml / g resin), and in the case of tryptophan-containing peptides of a thiol to remove the indolene formyl group, preferably ethanedithiol (0.5 ml / g resin), the mixture was condensed with cooling with liquid N 2 hydrogen fluoride ( 10 ml / g resin). The mixture was allowed to warm to 0 ° C and stirred at this temperature for 45 min. The hydrogen fluoride was then stripped off in vacuo and the residue was washed with ethyl acetate in order to remove remaining scavengers. The peptide was extracted with 30% acetic acid, filtered and the filtrate
  • the peptide resin (Pam or Merrifield resin) was suspended in DMF (15 ml / g resin) and, after addition with hydrazine hydrate (20 equivalents), stirred for 2 days at room temperature. For working up, the resin was filtered off and the filtrate was evaporated to dryness. The residue was crystallized from DMF / Et 2 O or MeOH / Et 2 O.
  • the purity of the end products obtained was determined using analytical HPLC (stationary phase: 100 ⁇ 2, 1 mm VYDAC C-18, 5 ⁇ , 300 ⁇ ; mobile phase CH 3 CN / H 2 O gradient, buffered with 0.1% TFA, 40 ° C). Amino acid analysis and fast atom bombardment mass spectroscopy were used for characterization.
  • Boc-Trp (CHO) -OH Boc-Gly-OH Boc-Arg (Tos) -OH
  • step 1-6 and 14-16 were carried out according to Ala).
  • the peptide resin was dried in vacuo; the yield was 2.2 g. 1.1 g of the resin thus obtained was subjected to HF cleavage according to All.
  • the crude product (411 mg) was purified by gel filtration (SEPHADEX® G-10) and medium pressure chromatography (cf. AIV; 50-65% A; 0.25% min -1 ). 242 mg of pure product were obtained.
  • SEPHADEX® G-10 medium pressure chromatography
  • step 2-4 were carried out according to Alb).
  • the peptide resin obtained was in
  • Boc-Glu (OChx) -OH implemented.
  • Example 7 Analogously to Example 7 can be prepared (for the synthesis of

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne de nouveaux peptides ayant la formule X-A-Y, dans laquelle A, X, et Y ont la signification donnée dans la description, et leur procédé de production. Ces nouveaux peptides sont utiles pour traiter des maladies.
EP90900861A 1988-12-12 1989-12-02 Nouveaux peptides derives du facteur de necrose de tumeurs (tnf) Withdrawn EP0447476A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3841759 1988-12-12
DE3841759A DE3841759A1 (de) 1988-12-12 1988-12-12 Neue tnf-peptide

Publications (1)

Publication Number Publication Date
EP0447476A1 true EP0447476A1 (fr) 1991-09-25

Family

ID=6368955

Family Applications (1)

Application Number Title Priority Date Filing Date
EP90900861A Withdrawn EP0447476A1 (fr) 1988-12-12 1989-12-02 Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)

Country Status (5)

Country Link
EP (1) EP0447476A1 (fr)
JP (1) JPH04502157A (fr)
CA (1) CA2005059A1 (fr)
DE (1) DE3841759A1 (fr)
WO (1) WO1990006945A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5728680A (en) * 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
US5807830A (en) * 1987-12-30 1998-09-15 Cytoven J.V. Method for treatment of purulent inflammatory diseases
US5811399A (en) * 1988-12-14 1998-09-22 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants
US5770576A (en) * 1989-08-30 1998-06-23 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
SE9603468D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
SE9603461D0 (sv) * 1996-09-23 1996-09-23 Astra Ab New compounds
DE69938743D1 (de) 1998-08-14 2008-06-26 Rudolf Lucas TNF-Peptide zur Behandlung von Ödemen
EP2009023A1 (fr) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Nouveaux peptides et leur utilisation pour le traitement de l'oedème
AT506150B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT506151B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
KR20230038600A (ko) * 2014-03-04 2023-03-20 아펩티코 포어슝 운트 엔트빅크룽 게엠베하 폐내 염증의 완화

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH064675B2 (ja) * 1985-07-29 1994-01-19 伝一 水野 抗腫瘍性ポリペプチド
DE3620656A1 (de) * 1986-06-20 1987-12-23 Basf Ag Polypeptide mit lymphotoxin-aktivitaet oder lymphotoxin-aehnlicher aktivitaet, ihre herstellung und verwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9006945A1 *

Also Published As

Publication number Publication date
WO1990006945A1 (fr) 1990-06-28
CA2005059A1 (fr) 1990-06-12
DE3841759A1 (de) 1990-06-13
JPH04502157A (ja) 1992-04-16

Similar Documents

Publication Publication Date Title
WO1990006943A2 (fr) Nouveaux peptides tnf
EP0447476A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
EP0447430A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
WO1990006942A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
DE3939797A1 (de) Neue vom neuropeptid y abgeleitete peptide
WO1990006946A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
WO1990006940A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
EP0447472A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
WO1990006939A1 (fr) Peptides tnf
EP0447431A1 (fr) Nouveaux peptides derives du facteur de necrose tumeurs (tnf)
EP0447429A1 (fr) Nouveaux peptides derives du facteur de necrose de tumeurs (tnf)
WO1992011285A1 (fr) Nouveaux peptides constituant des facteurs de necrose tumorale
DE4041188A1 (de) Neue tnf-peptide
EP0570375A1 (fr) Nouveaux peptides a activite anticoagulante.
DE4041189A1 (de) Neue-tnf-peptide

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19910508

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE ES FR GB IT LI NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

17Q First examination report despatched

Effective date: 19920709

18W Application withdrawn

Withdrawal date: 19920701